Trevi Therapeutics, Inc. (TRVI) Cash Flow Statement
Trevi Therapeutics, Inc. (TRVI) generated -$52.6M of operating cash flow over the twelve months to 2026-06-30, spent $238000 on capital expenditure and had free cash flow of -$52.9M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TRVITrevi Therapeutics, Inc.Follow TRVI — free
—
Price chart with a free account
- Market cap
- 1.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -23.1 | -29.0 | -28.9 | -28.2 | -31.7 | -38.3 | -42.1 | -52.6 | |
| Capital expenditure | 0.0 | 0.0 | — | 0.2 | 0.1 | 0.0 | 0.0 | -0.2 | |
| Free cash flow | -23.1 | -29.0 | — | -28.3 | -31.8 | -38.3 | -42.1 | -52.9 | |
| Dividends paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Stock-based compensation | 1.1 | 2.4 | 2.5 | 2.3 | 2.2 | 3.6 | 5.2 | — |
USD millions · SEC XBRL
Trevi Therapeutics, Inc. — questions
- What is Trevi Therapeutics, Inc.'s operating cash flow?
- -$52.6M over the twelve months to 2026-06-30.
- How much does Trevi Therapeutics, Inc. spend on capital expenditure?
- $238000 over the twelve months to 2026-06-30.
- What is Trevi Therapeutics, Inc.'s free cash flow?
- -$52.9M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Trevi Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.